Clinical trial Recruiting at 1 site Early Phase 1 Interventional Ages 18 to 35 Women only

Nebulized neostigmine/atropine versus nebulized lidocaine for post-dural puncture headache after cesarean delivery

Official title: Comparison of Nebulized Neostigmine/Atropine Versus Lignocaine in Treating Acute Post-dural Puncture Headache Following Subarachnoid Block in Parturient Undergoing Elective Cesarean Section. A Randomized, Clinical Trial.

Run by Minia University · NCT06824025 · Data updated 2026-11-12

This trial tests whether inhaled (nebulized) neostigmine with atropine relieves post-dural puncture headache better than inhaled lidocaine in women who develop headache after spinal anesthesia for elective cesarean delivery.

More Post-Dural Puncture Headache trials

Quick facts

PhaseEarly Phase 1
Study typeInterventional
Ages18 Years to 35 Years
SexWomen only
Enrollment111 (estimated)
SponsorMinia University
Academic / other
Locations1 site (Minya)
StatusRecruiting
StartedFebruary 20, 2025
Main results expectedJanuary 1, 2027
Study endsJanuary 5, 2027
Registry record updatedAugust 12, 2026
Trial IDNCT06824025 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are women aged 18–35 who develop moderate-to-severe post-dural puncture headache after elective cesarean delivery under spinal anesthesia (VAS ≥4 and Lybecker score ≥2).

Probably not a fit

Patients with pregnancy-induced hypertension, active or historical bronchial asthma, prior migraine or trigeminal neuralgia, postpartum hemorrhage, emergency cesarean section, need for conversion to general anesthesia, failed spinal anesthesia, or those who refuse participation are not eligible and are unlikely to benefit from this protocol.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This single-center, randomized interventional early phase I trial enrolls parturients who develop post-dural puncture headache after elective cesarean section under spinal anesthesia. Eligible women (aged 18–35) with moderate-to-severe headache (VAS ≥4 and Lybecker score ≥2) are randomized to receive nebulized neostigmine/atropine or nebulized lidocaine (total 4 ml). Headache intensity, need for rescue analgesia, and adverse events are followed after treatment to compare symptom relief and safety. The trial is conducted at Minia University and focuses on short-term headache outcomes and tolerability of the inhaled interventions.

Why it matters

Potential benefit: If successful, this noninvasive inhaled treatment could provide faster relief of PDPH symptoms and reduce the need for invasive procedures like an epidural blood patch.

How similar studies have gone: This inhaled neostigmine/atropine approach is largely novel for PDPH and prior related therapies (topical/local agents and systemic adjuvants) have shown mixed or limited evidence of benefit.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* 18-35 years old parturient with post partum headache after elective CS under spinal anesthesia with visual analog score (VAS) ≥ 4 \[14\] and Lybecker classification score ≥ 2

Exclusion Criteria:

* Pregnancy induced hypertension
* Emergency C.S
* Asthmatic candidates
* Previous history of migraine or trigeminal neuralgia
* History of bronchial asthma
* Post partum hemorrhage
* Need for GA , failed spinal anesthesia
* Patient refusal

Where it's running

  • Minia University
    Minya, Egypt
    Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.